Article

Evaluation of KRAS <sup>G12C</sup> Inhibitor Responses in Novel Murine KRAS <sup>G12C</sup> Lung Cancer Cell Line Models

2022-08-20

Abstract excerpt

The KRAS(G12C) mutation is the most common genetic mutation in North American lung adenocarcinoma patients. Recently, direct inhibitors of the KRAS G12C protein have been developed and demonstrate clinical response rates of 37-43%. Importantly, these agents fail to generate durable therapeutic responses with median progression-free survival of ~6.5 months. To provide models for further preclinical improvement of...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3dd2a534-370d-5f45-82c8-9f3076d63e21
DOI: 10.1101/2022.08.19.504555

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Evaluation of KRAS <sup>G12C</sup> Inhibitor Responses in Novel Murine KRAS <sup>G12C</sup> Lung Cancer Cell Line ModelsDOI 10.1101/2022.08.19.504555Read

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS <sup>G12D</sup> -driven non-small cell lung cancerSemantic proximity Read

Targeting KRAS G12C in non-small cell lung cancer: Breakthrough inhibitors and combination approaches.Semantic proximity Read

KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.Semantic proximity Read

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.Semantic proximity Read

Overcoming KRAS-Mutant Lung Cancer.Semantic proximity Read

Kras G12C- and G12D-driven lung cancers differ in oncogenic potency, immunogenicity, and relapse after Kras inhibition in mouse models.Semantic proximity Read

Acquired Resistance to KRASG12C Inhibition in Cancer.Semantic proximity Read

Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growthSemantic proximity Read

KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma.Semantic proximity Read

The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer.Semantic proximity Read

Advances in the treatment of KRASG12C mutant non–small cell lung cancerSemantic proximity Read

Multiplexed identification of RAS paralog imbalance as a driver of lung cancer growthSemantic proximity Read